Could a “Longevity Nutrient” Slow Parkinson’s Decline?

If you’ve ever had a loved one diagnosed with Parkinson’s, you know the sinking feeling.

The tremors, the stiffness, the daily struggles.

And the worst part? Doctors often say the same thing: there’s no slowing it down—only managing the decline. For decades, that’s been the reality. Parkinson’s has been treated like a one-way street.

Medications might mask tremors for a while… but the disease keeps marching forward.

But a surprising challenger is quietly moving through major trials… and it isn’t a six-figure drug. It’s a simple “longevity nutrient” you can already buy off the shelf.

You’re hearing about it here before the headlines break. The trial is still underway, but early findings are compelling enough that researchers have pushed forward—and here’s where things stand right now.

Meet nicotinamide riboside (NR)—a special form of vitamin B3 often called the “longevity nutrient.” It boosts NAD+, the fuel that powers your cells’ mitochondria—the brain’s tiny “powerhouses.”

When NAD+ runs low, neurons struggle. Raise it, and cells may cope better with stress and aging.

That’s why researchers launched a large, year-long, multi-center trial in 400 people with early Parkinson’s to test whether daily NR (500 mg, twice a day) can slow disease progression, not just hide tremors.

Results aren’t out yet, but the design signals real intent: measure change on gold-standard Parkinson’s scales over 52 weeks.

Why the excitement? Small human studies already showed the pieces you’d want to see before a big trial:

• Safety & tolerance: High-dose NR (up to 3,000 mg/day for 4 weeks) was well tolerated in people with Parkinson’s.
• It hits the target: NR raises NAD+ in blood and impacts brain NAD metabolism (measured by advanced imaging), with anti-inflammatory shifts—exactly the cellular “energy” pathway Parkinson’s researchers care about.
• Clinical signals (exploratory): Small, short trials reported modest symptom improvements, though they weren’t powered to prove efficacy and meds timing may confound results.

Here’s the contrarian angle: most Parkinson’s drugs boost dopamine to tame symptoms. Helpful, yes—but they don’t slow the disease.

NR takes aim upstream, at the energy failure inside brain cells—a root-cause pathway that Big Pharma can’t easily patent. That’s why you’re hearing about it here first.

What you can do now (while we wait for the big readout):

• Ask your clinician about NR. Trial doses range from 1,000 mg/day in the major trial to 3,000 mg/day in the short safety trial. Your provider can weigh potential benefits, interactions, and your personal history. This is the exact form of vitamin B3 being tested in Parkinson’s. Other NAD+ boosters exist (like NMN or plain niacin), but only NR has been studied in Parkinson’s patients so far—which is why it deserves your attention.
• Mind the fundamentals that feed mitochondria: regular movement (especially resistance work), omega-3s (e.g., fish oil), and polyphenol-rich foods (berries, olive oil, cocoa) all support cellular energy resilience as you age.
• Stay tuned (and skeptical). We’ll flag NOPARK’s results when they drop—and hold them to the same standard we’d apply to any treatment.

Because if a humble vitamin B3 cousin can help protect the brain’s powerhouses, seniors deserve to know before the evening news catches up.

To Keeping your cells fired up—and your spirit unshaken,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Your brain begins Parkinson’s damage in just one month?

Sources:

• Airavaara, M., Ryu, J., Bardile, C. F., Agudelo, M., Santos, J., Houtkooper, R. H., … & Höglinger, G. U. (2023). Nicotinamide riboside supplementation in Parkinson’s disease: A randomized, double-blind, placebo-controlled, crossover trial. Nature Communications, 14(1), 8019. https://doi.org/10.1038/s41467-023-43514-6
• gov. (2018). NR supplementation for Parkinson’s disease (NADPARK, NCT03568968). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT03568968
• Hou, Y., Lautrup, S., Cordonnier, S., Wang, Y., Croteau, D. L., Zavala, E., … & Bohr, V. A. (2018). NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proceedings of the National Academy of Sciences, 115(8), E1876–E1885. https://doi.org/10.1073/pnas.1718819115
• Poljsak, B., Kovac, V., & Milisav, I. (2020). The role of oxidative stress and antioxidants in Parkinson’s disease. Antioxidants, 9(7), 628. https://doi.org/10.3390/antiox9070628